Company intelligence / Profile preview

Gate2Brain

Barcelona, Catalonia, Spaingate2brain.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Gate2Brain’s lead asset targets pediatric brain tumors with intact blood-brain barriers. The company has demonstrated preclinical proof-of-concept using its proprietary peptide shuttle technology to deliver drugs—including antibodies—across the blood-brain barrier. Clinical trials are planned to start in children at Sant Joan de Déu hospital around 2026.

Therapeutic areas: OncologyNeurology
Modalities: Peptide-based drug delivery shuttlesAntibody delivery (platform enables this)Small molecules (delivered via peptide shuttles)
Industry: Biotech

Drug pipeline

1 asset

G2B-002

Preclinical

Partnerships

Academic founding partners include IRB Barcelona, University of Barcelona, and Sant Joan de Déu Research Institute/Sant Joan de Déu Hospital. No major pharma partnerships disclosed yet.

Beyond the preview

Go deeper on Gate2Brain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gate2Brain.

Explore the full profile